ライフサイエンスコーパス: zidovudine

1 ofovir, in 18% for stavudine, and in 10% for zidovudine.

2 cation with a superior resistance profile to zidovudine.

3 ceived single-dose nevirapine and 4 weeks of zidovudine.

4 Kenyan perinatal cohort receiving antenatal zidovudine.

5 All women were treated with antenatal zidovudine.

6 xyurea treatment or stopped prematurely with zidovudine.

7 of nevirapine plus 1 week of daily doses of zidovudine.

8 vir, lamivudine, zalcitabine, stavudine, and zidovudine.

9 to either nevirapine alone or nevirapine and zidovudine.

10 s support only the potential clinical use of zidovudine.

11 tenofovir disoproxil fumarate, abacavir, or zidovudine.

12 antiretroviral (ARV) combinations containing zidovudine.

13 Mice (C57Bl/6) were administered with AZT (Zidovudine 100 mg/kg/day), 3TC (Lamivudine 50 mg/kg/day)

14 In HIV-2, resistance to zidovudine (3'-azido-3'-deoxythymidine (AZT)) and other

15 so increases the sensitivity of the virus to zidovudine (3'-azido-3'-deoxythymidine; AZT).

16 All of the mothers received zidovudine 300 mg orally twice daily from 34 weeks' gest

17 00 mg each night) plus lamivudine 150 mg and zidovudine 300 mg twice daily (or approved alternative b

18 tor regimen containing a lamivudine (150 mg)-zidovudine (300 mg) combination tablet (COM) and abacavi

19 At week 96, patients receiving zidovudine/3TC had lost limb fat, and those receiving em

20 hers used prenatal ARV prophylaxis (prenatal zidovudine, 43.9%; HAART, 52.1%).

21 r babies within 72 h of birth; regimen A) or zidovudine (600 mg orally at labour onset and 300 mg eve

22 with symptomatic KSHV-MCD received high-dose zidovudine (600 mg orally every 6 hours) and the oral pr

23 Mutations with preferential zidovudine activity, K65R or K70E, occurred in 5.3% of i

24 mary damage to mitochondrial DNA, induced by zidovudine administration or homozygous mutation of mito

25 three NRTIs selected from an algorithm (eg, zidovudine after failure with tenofovir and vice versa;

26 A 1-week "tail" of lamivudine and zidovudine after SD-NVP decreases the risk of resistance

27 n was significantly lower with ART than with zidovudine alone (0.5% in the combined ART groups vs. 1.

28 frequent with tenofovir-based ART than with zidovudine alone (16.9% vs. 8.9%, P=0.004); preterm deli

29 as higher with tenofovir-based ART than with zidovudine alone (2.9% vs. 0.8%, P=0.03).

30 frequent with zidovudine-based ART than with zidovudine alone (20.5% vs. 13.1%, P<0.001).

31 y higher with zidovudine-based ART than with zidovudine alone (21.1% vs. 17.3%, P=0.008), and the rat

32 frequent with zidovudine-based ART than with zidovudine alone (23.0% vs. 12.0%, P<0.001) and was more

33 differences between tenofovir-based ART and zidovudine alone (P=0.10 and P=0.43).

34 y lower rates of early HIV transmission than zidovudine alone but a higher risk of adverse maternal a

35 wo- or three-drug ART regimen is superior to zidovudine alone for the prevention of intrapartum HIV t

36 Antenatal ART included zidovudine alone in 23%; combinations without protease i

37 artum "tail" of tenofovir and emtricitabine (zidovudine alone); zidovudine, lamivudine, and lopinavir

38 dine or emtricitabine and tenofovir), versus zidovudine alone.

39 r to those in cellular experiments that used zidovudine alone.

40 m transmission occurred in 24 infants in the zidovudine-alone group (4.8%; 95% confidence interval [C

41 (140 infants), with an increased rate in the zidovudine-alone group (P=0.03 for the comparisons with

42 e of three regimens: zidovudine for 6 weeks (zidovudine-alone group), zidovudine for 6 weeks plus thr

43 in the Americas and South Africa (566 in the zidovudine-alone group, 562 in the two-drug group, and 5

44 alogs (>1,000-fold increase in resistance to zidovudine and >250-fold to stavudine) but not to other

45 3% in 484 babies who received nevirapine and zidovudine and 20.9% in 468 babies who received nevirapi

46 rth, 34 (7.7%) babies who had nevirapine and zidovudine and 51 (12.1%) who received nevirapine only w

47 KSHV thymidine kinase can phosphorylate zidovudine and ganciclovir to toxic moieties, and direct

48 It can also phosphorylate zidovudine and ganciclovir to toxic moieties, enabling t

49 In contrast, the combination of zidovudine and gemcitabine was no more effective than ge

50 Subjects received lamivudine plus zidovudine and indinavir (indinavir group), efavirenz pl

51 onfirmed the relative sensitivity of PERV to zidovudine and its resistance to all other RTIs.

52 g regimen containing efavirenz combined with zidovudine and lamivudine (but not efavirenz combined wi

53 (indinavir arm) to that of a combination of zidovudine and lamivudine (dual-nucleoside arm).

54 Starting with zidovudine and lamivudine combined with efavirenz (but n

55 lamivudine combined with efavirenz (but not zidovudine and lamivudine combined with nelfinavir) appe

56 regimens, starting with a regimen including zidovudine and lamivudine or a regimen including didanos

57 iteria for noninferiority to a fixed dose of zidovudine and lamivudine plus efavirenz and proved supe

58 d a randomized trial of initial therapy with zidovudine and lamivudine plus either nevirapine or rito

59 d in better outcomes than did treatment with zidovudine and lamivudine plus nevirapine.

60 sion, antiretroviral treatment consisting of zidovudine and lamivudine plus ritonavir-boosted lopinav

61 ricitabine group) or a regimen of fixed-dose zidovudine and lamivudine twice daily plus efavirenz onc

62 tion with either didanosine and stavudine or zidovudine and lamivudine with therapy involving two con

63 vir monotherapy, followed by the addition of zidovudine and lamivudine.

64 Estimated risks of HIV-1 transmission in the zidovudine and nevirapine groups were 10.3% and 8.1% at

65 ible to the reverse transcriptase inhibitors zidovudine and nevirapine.

66 ndow in which use of antiviral agents (i.e., zidovudine and raltegravir) may be of benefit.

67 nd gemcitabine) and antiviral drugs (such as zidovudine and ribavirin), have been shown to depend, at

68 rical comparison group who received prenatal zidovudine and SD-NVP.

69 Women received zidovudine and single dose nevirapine for PMTCT and were

70 f at least 350 cells per cubic millimeter to zidovudine and single-dose nevirapine plus a 1-to-2-week

71 ntiretroviral therapy (ART) as compared with zidovudine and single-dose nevirapine to prevent transmi

72 As tenofovir and abacavir have replaced zidovudine and stavudine in antiretroviral regimens, thy

73 nd enzyme level for cross-resistance between zidovudine and stavudine, and they suggest a possible ef

74 e resistance with different implications for zidovudine and tenofovir cross-resistance, the primary c

75 s may also help explain the effectiveness of zidovudine and valganciclovir in the treatment of KSHV-M

76 pathogenesis of KSHV-MCD and the activity of zidovudine and valganciclovir in this disease.IMPORTANCE

77 -activated cytotoxic therapy using high-dose zidovudine and valganciclovir, can control symptoms and

78 received HAART (nevirapine, lamivudine, and zidovudine) and women who did not receive HAART.

79 04 (67%) children on stavudine, 103 (65%) on zidovudine, and 105 (64%), on abacavir (p=0.63; zidovudi

80 en were randomised: 156 to stavudine, 159 to zidovudine, and 165 to abacavir.

81 5 (81%) ART-naive children in the stavudine, zidovudine, and abacavir groups, respectively, had viral

82 Using sulforhodamine b, zidovudine, and bovine serum albumin as model hydrophili

83 nucleoside reverse-transcriptase inhibitors, zidovudine, and didanosine were not permitted.

84 was the main removal mechanism for abacavir, zidovudine, and emtricitabine, with half-lives (t1/2,pho

85 f treatment with a combination of indinavir, zidovudine, and lamivudine (indinavir arm) to that of a

86 illimeter) to receive coformulated abacavir, zidovudine, and lamivudine (the nucleoside reverse-trans

87 e triple-nucleoside combination of abacavir, zidovudine, and lamivudine was virologically inferior to

88 ic procedure on three HIV drugs, (Indinavir, Zidovudine, and Nevirapine), discovered unique interacti

89 Zidovudine antiretroviral therapy did not confer a signi

90 IV-infected women and their infants received zidovudine as well as single-dose nevirapine or placebo.

91 enofovir disoproxil fumarate, amdoxovir, and zidovudine, as well as four natural endogenous dNTP.

92 in decline was steeper in patients receiving zidovudine (azidothymidine [AZT], -3.64 g/dL vs. no AZT,

93 ideoxycytidine (ddC), cytarabine (ara-C) and zidovudine (Azidothymidine, AZT).

94 4T) >> lamivudine (3TC) > tenofovir (PMPA) > zidovudine (AZT) > abacavir (metabolized to carbovir, CB

95 dine or emtricitabine): efavirenz (EFV) plus zidovudine (AZT) (n = 524); EFV plus tenofovir (TDF) (n

96 y (WBRT) and antiviral therapy consisting of zidovudine (AZT) and ganciclovir (GCV; MST 41.3 +/- 3.3

97 F77L), and all were found to be sensitive to zidovudine (AZT) and other drugs.

98 eoside reverse transcriptase (RT) inhibitors zidovudine (AZT) and tenofovir and the integrase inhibit

99 r CTNAs-acyclovir (ACV), cytarabine (Ara-C), zidovudine (AZT) and zalcitabine (ddC)-we show that TDP1

100 Stavudine (d4T) and zidovudine (AZT) are thymidine analogs widely used in th

101 to inhibit the incorporation and excision of zidovudine (AZT) by HIV-1 RT using DNA/DNA and RNA/DNA T

102 nd regimen switches from stavudine (d4T) and zidovudine (AZT) regimens have been well described but d

103 ver, it has only recently been proposed that zidovudine (AZT) resistance can involve the excision of

104 monophosphate (AZTMP) in vitro and increases zidovudine (AZT) resistance in vivo.

105 We recently reported that zidovudine (AZT) selected for the Q509L mutation in the

106 AART drugs [ritonavir, indinavir, lopinavir, zidovudine (AZT), abacavir, stavudine, didanosine (ddI),

107 develop resistance to the nucleoside analog zidovudine (AZT), HIV-2 RT does not appear to use this p

108 The NRTIs zidovudine (AZT), stavudine (d4T), didanosine (ddI), and

109 ster of acyclovir, and the 5'-valyl ester of zidovudine (AZT), was purified from Caco-2 cells derived

110 nce testing was done for 220 HIV-1-infected, zidovudine (AZT)-exposed pregnant women and 24 of their

111 rent from either the wild-type (WT) T or the zidovudine (AZT)-selected T215Y/F.

112 han has previously been demonstrated between zidovudine (AZT)-triphosphate resistance data at the rev

113 to lamivudine and/or hypersusceptibility to zidovudine (AZT).

114 y defines such a mutagen, 3'-azidothymidine [zidovudine (AZT)], used widely in the treatment and prev

115 7-fold) and decreased hypersusceptibility to zidovudine (AZT; 1.4-2.2-fold).

116 ed ART was associated with higher rates than zidovudine-based ART of very preterm delivery before 34

117 ivery before 37 weeks was more frequent with zidovudine-based ART than with zidovudine alone (20.5% v

118 adverse events was significantly higher with zidovudine-based ART than with zidovudine alone (21.1% v

119 t of less than 2500 g was more frequent with zidovudine-based ART than with zidovudine alone (23.0% v

120 vudine, lamivudine, and lopinavir-ritonavir (zidovudine-based ART); or tenofovir, emtricitabine, and

121 highest among infants whose mothers received zidovudine-based ART.

122 m cells, from newborns exposed in utero to a zidovudine-based ARV combination present cytogenetic and

123 nterestingly the sEPD significantly improved zidovudine bioavailability by 100% as compared to oral g

124 Zidovudine blocked formation of late viral replication p

125 hs of breastfeeding plus prophylactic infant zidovudine (breastfed plus zidovudine), or formula feedi

126 In multivariate analyses, patients on zidovudine-containing regimens had a greater reduction i

127 nodeficiency virus (HIV) is usually based on zidovudine-containing regimens, despite potential toxici

128 itor-based first-line regimen, followed by a zidovudine-containing, protease inhibitor (PI)-based sec

129 imens: single-dose nevirapine plus 1 week of zidovudine (control regimen) or the control regimen plus

130 Mice were treated with darunavir, zidovudine, darunavir + zidovudine, or control.

131 assigned 1844 women in Thailand who received zidovudine during the third trimester of pregnancy to re

132 viral therapy with efavirenz plus lamivudine-zidovudine (EFV+3TC-ZDV), atazanavir plus didanosine-EC

133 her, treatment with the antiretroviral agent zidovudine either significantly reduced or completely re

134 Lamivudine, zidovudine, emtricitabine, and tenofovir had no effects.

135 Lamivudine, abacavir, zidovudine, emtricitabine, and tenofovir significantly i

136 were randomly assigned to receive lamivudine/zidovudine, emtricitabine/tenofovir, or lopinavir/ritona

137 We evaluated zidovudine-experienced patients for whom treatment with

138 s only the genetic variants, creatinine, and zidovudine exposure remained significant.

139 extended nevirapine) or with nevirapine plus zidovudine (extended dual prophylaxis) until the age of

140 om treatment with indinavir, lamivudine, and zidovudine failed, for indinavir-resistant minority vari

141 s, 14 weeks, or 28 weeks, or nevirapine plus zidovudine for 14 weeks.

142 (HIV-1) infection to one of three regimens: zidovudine for 6 weeks (zidovudine-alone group), zidovud

143 he first 8 days of life (two-drug group), or zidovudine for 6 weeks plus nelfinavir and lamivudine fo

144 vudine for 6 weeks (zidovudine-alone group), zidovudine for 6 weeks plus three doses of nevirapine du

145 laxis with nevirapine or with nevirapine and zidovudine for the first 14 weeks of life significantly

146 ), or formula feeding plus 1 month of infant zidovudine (formula fed).

147 post-exposure prophylaxis of nevirapine plus zidovudine given to babies only reduced transmission of

148 loss of morphine, 4-methylumbelliferone, and zidovudine glucuronidation activity, but morphine glucos

149 ormula-fed group than for the breastfed plus zidovudine group (9.3% vs 4.9%; P = .003), but this diff

150 a single dose; babies in the nevirapine plus zidovudine group also received zidovudine twice daily fo

151 p) vs 9.0% (51 infants in the breastfed plus zidovudine group) (P = .04; 95% confidence interval for

152 (tenofovir group) or zidovudine-lamivudine (zidovudine group).

153 analysed in the stavudine group, 158 in the zidovudine group, and 164 in the abacavir group, and fol

154 tenofovir group and 4063 (73.2%) were in the zidovudine group.

155 no AZT, -2.08 g/dL), and patients receiving zidovudine had more anemia-related RBV dose reductions (

156 The genotoxicity of zidovudine has been established in experimental models.

157 drugs and HIV lipohypertrophy, stavudine and zidovudine have been implicated in the development of HI

158 high-level resistance to both lamivudine and zidovudine in HIV-2, and the combination of K65R, Q151M,

159 sdNVP), (2) WHO 2010 guidelines' "Option A" (zidovudine in pregnancy, infant nevirapine throughout br

160 oncentrations of nevirapine, lamivudine, and zidovudine in serum and whole breast milk from human imm

161 ble levels by using the antiretroviral drugs zidovudine, indinavir sulfate, and didanosine, demonstra

162 The peculiar mitochondrial pathology of zidovudine-induced mitochondrial DNA depletion, cytochro

163 ), but not the three-drug regimen containing zidovudine, lamivudine, and efavirenz (hazard ratio, 1.2

164 dine, and nelfinavir (hazard ratio, 1.06) or zidovudine, lamivudine, and efavirenz (hazard ratio, 1.4

165 The combination of zidovudine, lamivudine, and efavirenz is superior to the

166 ating therapy with the three-drug regimen of zidovudine, lamivudine, and efavirenz is the optimal cho

167 The initial use of zidovudine, lamivudine, and efavirenz resulted in a shor

168 ompared the initiation of HIV treatment with zidovudine, lamivudine, and either nevirapine or ritonav

169 jection of the HAART cocktail (consisting of zidovudine, lamivudine, and indinavir) to determine opti

170 patients who immediately began therapy with zidovudine, lamivudine, and indinavir.

171 ofovir and emtricitabine (zidovudine alone); zidovudine, lamivudine, and lopinavir-ritonavir (zidovud

172 ere randomized to receive either triple ARV (zidovudine, lamivudine, and lopinavir/ritonavir during p

173 dine, and efavirenz (hazard ratio, 0.63); or zidovudine, lamivudine, and nelfinavir (hazard ratio, 0.

174 eived the three-drug regimens beginning with zidovudine, lamivudine, and nelfinavir (hazard ratio, 1.

175 231 [48.5%]; ARR, 1.31; 95% CI, 1.13-1.52); zidovudine, lamivudine, and NPV (ZDV-3TC-NVP) (647 of 13

176 at received the four-drug regimen containing zidovudine, lamivudine, nelfinavir, and efavirenz and th

177 ere associated with high-level resistance to zidovudine, lamivudine, tenofovir, or abacavir.

178 ing initial combination therapy of indinavir-zidovudine-lamivudine (ACTG 343 and Merck 035).

179 er cubic millimeter received nevirapine plus zidovudine-lamivudine (the observational group).

180 or [NRTI] group) or lopinavir-ritonavir plus zidovudine-lamivudine (the protease-inhibitor group) fro

181 icitabine or lamivudine (tenofovir group) or zidovudine-lamivudine (zidovudine group).

182 HIV RNA per milliliter than did those in the zidovudine-lamivudine group (84 percent vs. 73 percent,

183 More patients in the zidovudine-lamivudine group than in the tenofovir-emtric

184 udine twice daily plus efavirenz once daily (zidovudine-lamivudine group).

185 ir-emtricitabine group vs. 70 percent in the zidovudine-lamivudine group; 95 percent confidence inter

186 with HIV-1: zidovudine-lamivudine-abacavir, zidovudine-lamivudine plus efavirenz, and zidovudine-lam

187 dividuals to receive didanosine-stavudine or zidovudine-lamivudine, combined with efavirenz and/or ne

188 Compared with zidovudine-lamivudine, the use of tenofovir-lamivudine o

189 r, zidovudine-lamivudine plus efavirenz, and zidovudine-lamivudine-abacavir plus efavirenz.

190 l treatment of subjects infected with HIV-1: zidovudine-lamivudine-abacavir, zidovudine-lamivudine pl

191 ced lipid changes; all levels increased with zidovudine/lamivudine (3TC) and abacavir/3TC (except tri

192 were randomized to receive sdNVP and either zidovudine/lamivudine (3TC), tenofovir/emtricitabine (FT

193 se inhibitor pairs most frequently used were zidovudine/lamivudine (66% of PYFU), stavudine/lamivudin

194 zidovudine/lamivudine (PI group) or abacavir/zidovudine/lamivudine (NRTI group) in a clinical trial t

195 nd 34 weeks gestation to lopinavir/ritonavir/zidovudine/lamivudine (PI group) or abacavir/zidovudine/

196 (monotherapy group, n = 69) or combined with zidovudine/lamivudine 300/150 mg twice daily (triple the

197 The antiretrovirals were zidovudine/lamivudine and nelfinavir or lopinavir/ritona

198 in utero tenofovir exposure; most were also zidovudine/lamivudine exposed.

199 Zidovudine/lamivudine plus efavirenz (3-drug regimen) vs

200 vudine/abacavir (triple-nucleoside regimen), zidovudine/lamivudine plus EFV (3-drug EFV regimen) or z

201 Subjects (n=64) were randomized to receive zidovudine/lamivudine/abacavir (triple-nucleoside regime

202 amivudine plus efavirenz (3-drug regimen) vs zidovudine/lamivudine/abacavir plus efavirenz (4-drug re

203 /lamivudine plus EFV (3-drug EFV regimen) or zidovudine/lamivudine/abacavir plus EFV (4-drug EFV regi

204 ; P = .001) first-line regimen compared with zidovudine/lamivudine/NNRTI, PI resistance at switch (6.

205 on treatment with indinavir, lamivudine, and zidovudine may occur slowly, depending on the genetic co

206 type was available, 4396 (50%) had received zidovudine monotherapy and 2949 (33%) combination ART.

207 ations of AIDS, despite having only received zidovudine monotherapy for a part of her life.

208 ldren receiving no antiretroviral therapy or zidovudine monotherapy only.

209 o therapy) and 9.6% during 1994-1996 (mostly zidovudine monotherapy) to 12.4% during 1997-1999 (dual-

210 1.32, 1.09-1.61), no ART (1.60, 1.32-1.94 vs zidovudine monotherapy), and antenatal combination ART (

211 5% CI 1.38-1.95), no ART (2.94, 2.43-3.57 vs zidovudine monotherapy), antenatal combination ART (1.40

212 ntenatal combination ART (1.40, 1.14-1.73 vs zidovudine monotherapy), WHO stage 4 HIV (2.42, 1.71-3.4

213 ntenatal combination ART (1.33, 1.12-1.60 vs zidovudine monotherapy).

214 On multivariate analysis, zidovudine monotherapy, a higher maternal viral load, an

215 associated with cARV therapy, compared with zidovudine monotherapy, with an adjusted odds ratio of 1

216 mother 200 mg; infant 2 mg/kg) and 7 days of zidovudine (mother 300 mg; infants 2 mg/kg) and lamivudi

217 pinavir-ritonavir plus either lamivudine and zidovudine or emtricitabine and tenofovir), versus zidov

218 Previous zidovudine or lamivudine use and presence at baseline of

219 n ritonavir-boosted lopinavir, combined with zidovudine or tenofovir plus lamivudine or emtricitabine

220 ophylactic infant zidovudine (breastfed plus zidovudine), or formula feeding plus 1 month of infant z

221 We aimed to compare stavudine, zidovudine, or abacavir as dual or triple fixed-dose-com

222 ated with darunavir, zidovudine, darunavir + zidovudine, or control.

223 The NRTIs were lamivudine + stavudine, zidovudine, or tenofovir.

224 ula fed) vs 86 infants (15.1% breastfed plus zidovudine) (P = .60; 95% confidence interval for differ

225 antiretroviral treatment arms: A (lamivudine-zidovudine plus efavirenz, n = 289), B (atazanavir, emtr

226 plus lopinavir and ritonavir for 7 days, (B) zidovudine plus enteric-coated didanosine for 30 days, o

227 f 3 intrapartum and postpartum regimens: (A) zidovudine plus enteric-coated didanosine plus lopinavir

228 The main ART regimens included stavudine/zidovudine plus lamivudine plus nevirapine/efavirenz.

229 bination regimens of efavirenz that included zidovudine plus lamivudine than those including tenofovi

230 ovir-disoproxil-fumarate plus emtricitabine, zidovudine plus lamivudine, or abacavir plus lamivudine)

231 ed comparison of nevirapine or abacavir with zidovudine plus lamivudine, routine viral load monitorin

232 These include interferon-alpha plus zidovudine (probably after 1-2 cycles of CHOP), intensiv

233 y of adding antiretroviral drugs to standard zidovudine prophylaxis in infants of mothers with human

234 Breastfeeding with zidovudine prophylaxis was not as effective as formula f

235 eeding (formula vs breastfeeding with infant zidovudine prophylaxis) interventions.

236 (FF) or breast-feed (BF) in combination with zidovudine prophylaxis.

237 s 123 ng/mL, but infants were also receiving zidovudine prophylaxis.

238 For abacavir and zidovudine, rapid transformation was attributable to hig

239 er stavudine failure in African populations, zidovudine rather than tenofovir may be preferred in sec

240 As expected, in the presence of zidovudine, recombinant viruses harboring the MNR RT fro

241 Darunavir and darunavir + zidovudine reduced albuminuria and histologic kidney inj

242 The nevirapine and zidovudine regimen is safe and easy to implement.

243 , 3.5%-6.7%) for the 14-week nevirapine plus zidovudine regimen, and 1.8% (95% CI, 1.0%-3.1%) for the

244 a compared with a short intrapartum/neonatal zidovudine regimen.

245 In order to understand the impact of zidovudine resistance and thymidine analog mutations (TA

246 Polymorphism 172K significantly suppressed zidovudine resistance caused by excision (e.g. thymidine

247 udine, and they suggest a possible effect of zidovudine resistance on susceptibility to lamivudine.

248 The zidovudine-resistant isolate exhibited low-level cross-r

249 hymidine analogue mutations had no effect on zidovudine sensitivity, the addition of Q151M together w

250 laxis with nevirapine or with nevirapine and zidovudine significantly reduces postnatal HIV-1 infecti

251 sed by the anti-HIV nucleoside drugs such as zidovudine, stavudine, and didanosine.

252 Cross-resistance between zidovudine, stavudine, and lamivudine was studied, using

253 S for lamivudine or emtricitabine, abacavir, zidovudine, stavudine, didanosine, and tenofovir and a s

254 V mutation: susceptibility to group 1 drugs (zidovudine, stavudine, tenofovir, and adefovir) increase

255 se transcriptase inhibitor (NRTI) backbones (zidovudine, stavudine, tenofovir, or abacavir, plus lami

256 Hence, the increased zidovudine susceptibility of RT(172K) results from its i

257 ied recombinant reverse transcriptase from a zidovudine-susceptible and -resistant pair of clinical i

258 years and anaemia was no more frequent with zidovudine than with the other drugs.

259 gimen (single-dose nevirapine plus 1 week of zidovudine); the control regimen plus nevirapine to age

260 o were treated with efavirenz and lamivudine/zidovudine; the planned treatment duration was 48 weeks.

261 alcohol use, metabolic/endocrine disorders, zidovudine therapy, and other infections.

262 ; or the control regimen plus nevirapine and zidovudine to age 14 weeks.

263 Using zidovudine to inhibit TK2, the synthesis of [(3)H]TTP fr

264 , or subtype, tenofovir was more likely than zidovudine to retain antiviral activity following first-

265 respectively, phosphorylate ganciclovir and zidovudine to toxic moieties.

266 with subtype C (45/65 [69.2%] in the NVP and zidovudine trial, Malawi) than in those in the HIVNET 01

267 t isolate demonstrated reduced inhibition by zidovudine triphosphate and stavudine triphosphate and,

268 virapine plus zidovudine group also received zidovudine twice daily for 1 week (4 mg/kg weight).

269 g pregnancy and breastfeeding) or AZT/sdNVP (zidovudine until delivery with single-dose nevirapine wi

270 infection, demographic characteristics, and zidovudine use were not associated with the development

271 s, including age, nadir CD4(+) T-cell count, zidovudine use, and comorbid conditions.

272 ir, acyclovir, emtricitabine, lamivudine and zidovudine) via both bio- and phototransformation proces

273 ovudine, and 105 (64%), on abacavir (p=0.63; zidovudine vs stavudine: hazard ratio [HR] 0.99 [95% CI

274 the proportions of mutations associated with zidovudine vs. tenofovir cross-resistance.

275 and the median infant serum concentration of zidovudine was 123 ng/mL, but infants were also receivin

276 After 14 days of monotherapy, lamivudine/zidovudine was added to the VCV arms; subjects receiving

277 3-drug antiretroviral therapy compared with zidovudine was associated with increased IL-2 expression

278 sure to abacavir, efavirenz, lamivudine, and zidovudine was significantly associated with increased r

279 udine, tenofovir, lamivudine, acyclovir, and zidovudine) was analyzed with three-dimensional ex vivo

280 troviral therapy in pregnancy, HAART use (vs zidovudine) was associated with higher odds of PTD (AOR,

281 One of these-efavirenz, lamivudine, and zidovudine-was the second most commonly used combination

282 oncentrations of nevirapine, lamivudine, and zidovudine were 0.67, 3.34, and 3.21 times, respectively

283 ine, stavudine, didanosine, zalcitabine, and zidovudine were reduced >20-fold, 26-fold, 6-fold, 4-fol

284 D4 cell count >250 cells/muL, most receiving zidovudine, were randomized at 28-38 weeks gestation to

285 B+ is not available, options A (short course zidovudine with single-dose nevirapine and an ARV "tail"

286 lpha, and 6 received consolidation high-dose zidovudine with valganciclovir.

287 of the T69del showed increased resistance to zidovudine, with little impact on other NRTI.

288 l load, CD4 cell count, and intention to use zidovudine, with the groups balanced by each site.

289 received SD-NVP, and some randomly received zidovudine (ZDV) as well.

290 studies reported outcomes of children given zidovudine (ZDV) plus lamivudine (3TC) as a 2-drug PEP r

291 Intrapartum intravenous zidovudine (ZDV) prophylaxis is a long-standing componen

292 Resistance to zidovudine (ZDV) results from thymidine analog resistanc

293 Short-course zidovudine (ZDV) was hypothesized to lower rates of NVP-

294 850 (ACTG 850) evaluated the penetration of zidovudine (ZDV), lamivudine (3TC), and amprenavir (APV)

295 ected with HIV-1 and HIV-2, all treated with zidovudine (ZDV), lamivudine (3TC), and lopinavir-ritona

296 es in cardiac function have been reported in zidovudine (ZDV)-exposed uninfected children.

297 human immunodeficiency virus (HIV)-infected zidovudine (ZDV)-intolerant/refusing pregnant women and

298 toxicities of the 5 most common NRTI pairs: zidovudine (ZDV)/lamivudine (3TC), ZDV/didanosine (ddI),

299 ed evaluable information on 2-drug regimens (zidovudine [ZDV]- or tenofovir [TDF]-based regimens), an

300 etroviral therapy regimens (lamivudine [3TC]/zidovudine [ZDV]/efavirenz [EFV], 3TC/ZDV/nelfinavir [NF